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and secondary fungal sepsis
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Abstract
Introduction: Fungal sepsis is an increasingly common problem in intensive care unit patients.Mortality from
fungal sepsis remains high despite antimicrobial therapy that is highly active against most fungal pathogens, a
finding consistent with defective host immunity that is present in many patients with disseminated fungemia.One
recently recognized immunologic defect that occurs in patients with sepsis is T cell “exhaustion” due to increased
expression of programmed cell death -1 (PD-1).This study tested the ability of anti-PD-1 and anti-programmed cell
death ligand -1 (anti-PD-L1) antagonistic antibodies to improve survival and reverse sepsis-induced
immunosuppression in two mouse models of fungal sepsis.
Methods: Fungal sepsis was induced in mice using two different models of infection, that is, primary fungal sepsis
and secondary fungal sepsis occurring after sub-lethal cecal ligation and puncture (CLP).Anti-PD-1 and anti-PD-L1
were administered 24 to 48 h after fungal infection and effects on survival, interferon gamma production, and
MHC II expression were examined.
Results: Anti-PD-1 and anti-PD-L1 antibodies were highly effective at improving survival in primary and secondary
fungal sepsis.Both antibodies reversed sepsis-induced suppression of interferon gamma and increased expression of
MHC II on antigen presenting cells.Blockade of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a second negative co-
stimulatory molecule that is up-regulated in sepsis and acts like PD-1 to suppress T cell function, also improved
survival in fungal sepsis.
Conclusions: Immuno-adjuvant therapy with anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies reverse sepsis-
induced immunosuppression and improve survival in fungal sepsis.The present results are consistent with previous
studies showing that blockade of PD-1 and CTLA-4 improves survival in bacterial sepsis.Thus, immuno-adjuvant
therapy represents a novel approach to sepsis and may have broad applicability in the disorder.Given the relative
safety of anti-PD-1 antibody in cancer clinical trials to date, therapy with anti-PD-1 in patients with life-threatening
sepsis who have demonstrable immunosuppression should be strongly considered.
Introduction
Sepsis, the host response to severe infection, is the 10th
leading cause of death in the United States and the
mostcommon cause of mortality in most intensive care
units [1,2].Improved treatment protocols have resulted
in the majority of patients surviving the initial 72 hours
of sepsis onset only to succumb later in the time course
of the disease [3].There is increasing recognition that a
state of impaired immunity follows the initial hyper-
inflammatory phase of sepsis [4-8].During this phase of
impaired immunity, patients are more susceptible to
secondary nosocomial infections, often with opportunis-
tic organisms that typically infect immunocompromised
individuals.One of the most important opportunistic
infections in patients in the ICU is Candida albicans
[9-12].Candida infections are currently the third or
* Correspondence: hotch@wustl.edu
1Department of Anesthesiology,Washington University School of Medicine,
660 South Euclid Ave., St. Louis, MO 63110, USA
Full list of author information is available at the end of the article
Chang et al. Critical Care 2013, 17:R85
http://ccforum.com/content/17/3/R85
© 2013 Chang et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
fourth most common cause of bloodstream infections in
many intensive care units.Although excellent antimicro-
bial therapy against most Candida species exists, mor-
tality remains high at approximately 30 to 40% for
fungal sepsis [10-12].
The fact that mortality from fungal infections remains
high despite the use of antimicrobial agents that are
highly active against fungal organisms, suggests that
defects in host immunity may contribute to the persis-
tent high mortality.Therefore, methods that improve
host immune function may be fundamental to improv-
ing survival. In this regard, recent studies suggest that
immuno-adjuvant therapy in invasive fungal infections
may be a viable strategy [13-15].IL-7, a pleuripotent
cytokine that enhances adaptive immunity throughim-
munostimulatory effects on CD4 and CD8 T cells,
caused an approximately1.7-fold improvement in survi-
val in a murine fungal sepsis model [13].In addition to
animal studies, a few clinical studies support the use of
immuno-adjuvant therapy in invasive fungal infections
[14,15].A randomized trial of interferon gamma (IFN-g),
a potent activator of macrophages and monocytes in
HIV patients with cryptococcal meningitis, showed that
treatment led to a significantly faster rate of clearing of
cerebrospinal fluid, a finding that has been shown to
correlate with survival [14].IFN-g is currently approved
for use in patients with chronic granulomatous disease
who have invasive fungal infections [15].
Another potential strategy for improving host immu-
nologic defenses that has shown efficacy in various
infectious models is the use of agents which up-regula-
teadaptive immunity by blocking inhibitory receptors
expressed on T lymphocytes [16-19].T cell activation is
carefully controlled by expression of positive and nega-
tive co-stimulatory molecules that prevent excessive T
cell function.CD28 is the classic positive co-stimulatory
receptor that, acting in conjunction with the T cell
receptor (TCR), induces T cells to proliferate and pro-
duce cytokines including, for example, IL-2 and IFN-g
that have extensive effects on other cells.To prevent
excessive T cell activation, lymphocytes express a num-
ber of negative co-stimulatory molecules that suppress
and down-regulate their function [18,19].
Programmed cell death-1 (PD-1) is a member of the
B7-CD28 superfamily that functions in an inhibitory role.
During T cell activation, PD-1 is rapidly induced and
expressed on the surface of CD4 and CD8 T cells where
it interacts with its ligands PD-L1 and PD-L2 [20-22].PD-
L1 is expressed on both hematopoietic and non-hemato-
poietic cells and its expression is highly up-regulated dur-
ing inflammatory states [20].Activation of PD-1 by its
ligands causes inhibition ofmanyT cell functions, includ-
ing proliferation, cytotoxic activity and cytokine produc-
tion.The essential role of PD-1 in regulating immunity is
demonstrated in studies showing that PD-1 knockout
mice develop autoimmune diseases, including cardio-
myopathy and a lupus-like syndrome [16,20,21].Increased
T cell expression of PD-1 is known to occur under condi-
tions of chronic antigenic stimulation, such as persistent
viral infections, and lead to T cell “exhaustion” [16,
17,20].These “exhausted” T cells are non-functional,
prone to undergo apoptosis, and are unable to participate
in an effective immune response, thereby contributing to
the chronic nature of the viral infections.Blockade of PD-
1using inhibitory antibodies has been shown to restore
T cell function, increase antiviral T cell responses, and
reduce viral load in certain infections [18,19].In addition
to viral infections, blockade of the PD-1 pathway has
improved survival in bacterial infections.Three indepen-
dent groups demonstrated that blockade of the PD-1
pathway decreased mortality in clinically-relevant animal
models of bacterial sepsis [23-25].The potential clinical
relevance of these animal studies is highlighted by recent
studies showing that PD-1 over-expression on circulat-
ing T cells from patients with sepsis correlated with
decreased T cell proliferative capacity, increased second-
ary nosocomial infections and mortality [26].
The purpose of this study was to determine if inhibi-
tion of the T cell negative co-stimulatory PD-1:PD-L1
pathwaycould reverse immune dysfunction and improve
survival in primary fungal infections and in secondary
fungal sepsis occurring after bacterial infection.Both the
anti-PD-1 and the anti-PD-L1 antibodysignificantly
improved survival in the two different models of fungal
sepsis.This improvement in survival was associated with
increased production of IFN-g, a cytokine which is criti-
cal in host defenses against fungal organisms, and
reversed the fungal-induced depression of HLA-DR
expression in monocytes and dendritic cells.Blockade of
cytotoxic T-lymphocyte antigen 4 (CTLA-4), a second
negative co-stimulatory molecule that suppresses T cell
function, also improved survival in primary and second-
ary fungal sepsis thereby supporting the concept that
immuno-adjuvant therapy offers a rational, new approach
to treatment of this highly lethal infection.
Materials and methods
Mice
Eight-to-ten-week-old male C57BL6 or CD1 mice were
purchased from Jackson Laboratory (Bar Harbor, ME,
USA) or Charles River Laboratories (Wilmington, MA,
USA), respectively.Procedures were approved by the Ani-
mal Studies Committee at Washington University School
of Medicine.
Flow cytometry antibodies and reagents
The following fluorescently labeled antibodies used for
flow cytometrywere purchased from BD Pharmingen
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(San Diego,CA, USA): BD Pharmingen: CD4-FITC (Cat.
# 553729), CD4-PeCy5 (Cat. # 553050), CD8-FITC (Cat.
# 553031), B220-PeCy5 (Cat. # 553091), CD11c-FITC
(Cat. # 553801), CD274-Pe (Cat. # 558091), CD152-Pe
(Cat. # 553720), IFNg-Pe (Cat. # 554412), I-A/I-E-Pe
(Cat. # 557000), CD16/CD32-Block (Cat. # 553142).
The following fluorescently labeled antibodies used for
flow cytometry were purchased from eBioscience (San
Diego, CA, USA): CD279-Pe (Cat. # 12-9985-82),
CD11a-FITC (Cat. # 11-0111-85), MHC classII-Pe (Cat.#
15-5322-82).
Anti-PD-1, anti-PD-L1 and anti-CTLA4 antibodies that
were used for in vivo inhibition studies were provided by
Bristol-Meyers Squibb (NewYork, NY; USA).The clones
for anti-PD-1 and anti-PD-L1 were 4H2 and 14D8, respec-
tively.Two different clones of anti-CTLA-4 were used.
Clone G1 and clone G2B were used for single-hit and
two-hit models of fungal sepsis, respectively.
Fungal sepsis models
Candida albicans(ATCC MYA-2430)was grown overnight
in Difco™Sabouraud dextrose broth medium (Sigma
Aldrich, St. Louis, MO;USA).Cells were harvested, washed
and suspended in saline to obtain an optical density of
either 0.5A600or 0.3A600 for single-hit or two-hit fungal
sepsis, respectively,as described [13].
Two-hit model of cecal ligation and puncture (CLP)
followed by Candida albicans
The CLP model was used to induce sub-lethal peritoni-
tis for use in the two-hit model as previously described
[13,27].Mice were anesthetized with isoflurane and a
midline abdominal incision was performed.The cecum
was ligated and punctured twice with a #27 gauge nee-
dle.The abdomen was closed in two layers and mice
injected subcutaneously with 1 ml of 0.9% normal saline
containing Buprenex(PharmaForce, Columbus, OH;
USA)(0.05 mg/kg) subcutaneously and allowed to
recover.Imipenem(Merck; Whitehouse Station, NJ; USA)
(2.5mg/kg) was given subcutaneously 24h post-CLP.
Three days post-CLP, surviving mice received 60 μl of
the 0.3A600Candida suspension via tail vein injection.
Three days post-CLP was selected as the time point to
challenge with Candida because of previous studies
which demonstrated that mice had increased susceptibil-
ity to Candida (consistent with impaired immunity) at
this time point [27].This dose of Candida caused <10%
mortality in naïve mice and, therefore, the much higher
mortality in mice that had undergone CLP prior to the
Candida challenge highlights the impaired immunity
that occurs following CLP.Mice received fluconazole
200 μ gintra-peritoneal (i.p.)five days after Candida.
Mice were treated with anti-PD-1 (200 μgs), anti-PD-L1
(200 μgs) or anti-CTLA-4 (100 μgs) antibodies begin-
ning at days 2 or 4 post Candida infection.
Primary Candida (single hit) studies
Unanesthetized mice were injected via tail vein with 50 μl
of the 0.5A600Candida suspension.Mice were allowed free
access to food and water throughout the study.Where spe-
cified, the anti-fungal agent fluconazole (200 μg) was
administered via i.p. injection.Fluconazole was used in
order to show that immunotherapy with anti-PD-1 was
effective when added to standard antimicrobial therapy of
fungal sepsis.Anti-PD-1 and anti-PD-L1 antibody adminis-
tration was started two days after the initial Candida
infection.Anti-CTLA-4 antibody therapy (50 ugs) was
initiated at four days post Candida infection.The percen-
tage of mice survival at Day 12 was recorded.
PD-1 expression in splenic immune cells following
Candida infection
In order to determine the effect of Candida on lympho-
cyte PD-1 expression following single-hit or two-hit fungal
infection, mice were injected with Candida as previously
described and spleens were harvested at multiple time
points post-Candida infection [13,27]. Splenocytes were
prepared and underwent immunostainingwith fluoro-
chrome-conjugated antibodies to CD4 T, CD8 T and
PD-1. Flow cytometric analysis (50,000 events/sample) was
performed on FACScan (Becton Dickinson, San Jose, CA,
USA) and Cell Quest software (BD Pharmigen; San Diego,
CA; USA) was utilized to analyze the data [13].
Quantitation of cytokines
Cytokines were quantified using ELISA Duosets from
Invitrogen (Camarillo, CA, USA) and R&D Systems
(Minneapolis, MN, USA) employing the μ Quant Scan-
ning Microplate Spectrophotometer (Bio-Tek Instru-
ments,Winooski, VT, USA) as described [13,24,27].
Determination of intracellular IFN-g production in CD4
and CD8 T cells
At Day 11, spleens were harvested and splenocyte suspen-
sions prepared as previously described [13]. Approximately
10 million splenocytes were plated in sterile wells with 1 ml
of complete RPMI 1640 media (Sigma Aldrich, St Louis,
MO; USA). Splenocytes were stimulated with anti-CD3 and
anti-CD28 and incubated overnight.Approximately 18 h
later, a sample of supernatant was obtained and analyzed for
secreted cytokines. Next, brefeldin A was added for an addi-
tional four hours incubation after which splenocytes were
harvested, washed and immunostained for CD4 or CD8.
Cells were then fixed,permeabilized and stained for intracel-
lular IFN-g.The percentage of cells positive for IFN-g was
determined by flow cytometry as previously described [13].
Statistical analysis
Data were analyzed with the statistical software Prism
(GraphPad, San Diego, CA, USA).Data are reported as
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the mean ± SEM.For comparison of two groups, the
Student’s t-test was employed. One-way ANOVA with
Tukey’s multiple comparison tests was used to analyze
data in which there were more than two groups. For
survival studies, a log rank test was used.Significance
was reported at P <0.05.
Results
Anti-PD-1 and anti-PD-L1 improve survival in two-hit
fungal sepsis
Disseminated fungal sepsis frequently occurs as a sec-
ondary hospital acquired infection in ICU patients with
impaired immunity [9,10].In order to mimic the state of
impaired immunity that exists in ICU patients, sub-
lethal CLP was performed prior to Candida infection as
described previously [13,27].Mice underwent CLP fol-
lowed three days later by Candida challenge.Mice were
treated by i.p. injection with either anti-PD-1 or anti-
PD-L1 antibody or saline diluent (control) starting 48 h
after Candida infection. Both anti-PD-1 and anti-PD-L1
antibody caused an approximate two-fold improvement
in survival in fungal sepsis compared to control (P <
0.01)and there was no difference in the two antibody
treatments (Figure 1A).Survival studies conducted with
isotype control antibodies showed no survival benefit
compared to saline control (data not shown).
Anti-CTLA-4 antibody improves survival in two-hit
fungal sepsis
CTLA-4is a negative co-stimulatory molecule that acts in
a fashion similar to PD-1 to induce suppression of T cell
function [22].Previous work from our group by Inoue
et al.showed thatanti-CTLA-4 antibody improved survival
in a peritonitis model of sepsis and in a two-hit model of
CLP followed by Candida [28].The study, examining anti-
CTLA-4 in the two-hit fungal sepsis model by Inoue et al.,
was a small preliminary investigation.To further support
the concept that inhibition of negative co-stimulatory
molecules represents a viable potential therapeutic
approach in fungal sepsis, we examined effects of anti-
CTLA-4 antibody in a more thorough manner in both pri-
mary and secondary (two-hit) models of fungal sepsis.
Anti-CTLA-4 antibody was administered 24 h after
Candida infection and survival was recorded.Anti-CTLA-
4 caused a significant improvement in survival compared
to mice receiving saline diluent(control), that is, 57.9%
versus 27.8%, respectively, P < 0.05, (Figure 1B).
Anti-PD-1, anti-PD-L1, and anti-CTLA-4 improve survival
in primary (single-hit) fungal sepsis
Anti-PD-1, anti-PD-L1 and anti-CTLA-4 were also tested
in primary (single-hit) Candida infection. Mice had tail
vein injection of Candida followed by i.p. injections of
anti-PD-1 antibody, anti-PD-L1 antibody, or saline diluent
at days 2, 5 and 8 following Candida.Mice treated with
anti-PD-1 or anti-PD-L1 antibody had improved survival
compared to control mice (73.3% and 70.0% for anti-PD-1
and anti-PD-L1, respectively, versus 34.5% for controls, P
< 0.01)Figure 2A. Studies of anti-CTLA-4 antibody also
demonstrated improved survival versus control mice; the
improvement in survivalwas very similar to that occurring
with anti-PD-1 and anti-PD-L1 antibody therapy, that is,
68.4% versus 31.5% for anti-CTLA-4 and control respec-
tively, P ≤0.05, Figure 2B. Studies of isotype control anti-
body for anti-CTLA-4 showed no difference compared to
saline controls (data not shown).
Lymphocyte PD-1 expression is increased in primary and
two-hit fungal sepsis
We examined expression of PD-1 on CD4 and CD8 T
cells following single-hit and two-hitCandida infection.
Mice were injected with Candidaand spleens were har-
vested on days 3, 5 and 7 following infection.Splenocyte
suspensions were prepared and stained for CD4 or CD8
and PD-1 as described previously [13].There was a signifi-
cant increase in PD-1 expression on CD4 T cells at all
three time points compared to Day 0 (Figure 3A).There
wasan increase in PD-1 expression in CD8 T cells at days
3 and 5 following Candida infection as well (Figure 3B).
PD-1 expression was quantitated in the two-hit model of
sepsis as well.PD-1 expression was increased on CD4 and
CD8 T cells at Day 3 following CLP (prior to Candida
infection).CD4 T cell PD-1 expression was also increased
at days 9 and 12 following CLP which corresponds to days
6 and 9 following the second-hit Candida infection
(Figure 3C).CD8 T cell PD-1 expression was increased at
Day 5 post CLP which corresponds to Day 2 following
the second-hit Candida infection but not at other times
(Figure 3D).
Anti-PD-1, anti-PD-L1 and anti-CTLA-4 increased IFN-g
production in fungal sepsis
One potential mechanism for the protective effect of
anti-PD-1, anti-PD-L1 and anti-CTLA-4 is to increase
IFN-g, a potent macrophage activator that has shown effi-
cacy in clinical trials of disseminated fungemia [14,15].
Thus, the effect of blockade of these inhibitory molecules
on IFN-g production was examined. To study effects in
the single-hit model, mice were injected via tail vein with
Candida and had dosing of anti-PD-1 (days 2, 5 and 8
post-infection) or anti-CTLA4 (days 4, 7 and 10 post-
infection). Mice were killed and spleens harvested on Day
12 post-infection. Splenocytes were prepared and stimu-
lated with anti-CD3 and anti-CD28 overnight as described
previously.Supernatants were harvested and IFN-g, IL-10
and IL-6 quantitated.Mice treated with anti-PD-1 had
increases in IFN-g, IL-10 and IL-6 compared to Candida-
infected mice that were treated with saline diluent
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Figure 1 Anti-PD-1, anti-PD-L1, and anti-CTLA-4 improve survival in two-hit fungal sepsis. Mice had sub-lethal cecal ligation and puncture
(CLP) and three days later had tail vein injection of 60 μl of the 0.3A600Candida suspension. (A)Anti-PD-1 or anti-PD-L1 antibody was
administered i.p. on days 5, 8 and 11 post-CLP. Fluconazole was administered by i.p. injection daily on days 8 to 12.Survival was recorded for
14 days. Data represent the combined results of four to five individual studies for both anti-PD-1 and anti-PD-L1.Both anti-PD-1 and anti-PD-L1
improved survival compared to control mice treated with saline diluent (P < 0.01). (B) Mice had sub-lethal cecal ligation and puncture (CLP) and
three days later had tail vein injection of Candida. Anti-CTLA-4 was administered i.p on Day 4 post-CLP. Fluconazole was administered by i.p.
injection daily on days 9 to 12.Anti-CTLA-4 improved survival compared to control mice treated with saline diluent (P < 0.05). Data represent
combined results of three studies. CTLA-4, cytotoxic T-lymphocyte antigen-4; PD-1, programmed cell death 1; PD-L1, programmed cell death
ligand 1.
Figure 2 Anti-PD-1, anti-PD-L1 and anti-CTLA-4 improve survival in single-hit fungal sepsis. Mice were injected via tail vein with 50 μl of
the 0.5A600Candida suspension. (A) Anti-PD-1 or anti-PD-L1 antibody was injected i.p. on days 2, 5 and 8 post-Candida injection.Fluconazole was
administered by i.p. injection daily on days 5 to 10. Mice treated with anti-PD-1 or anti-PD-L1 had significantly improved survival compared to
controls (P < 0.01). Data represent the combined results of three separate studies. (B) Anti-CTLA-4 was administered i.p on days 4, 7 and 10 post-
Candida. Fluconazole was administered by i.p. injection daily on days 10 and 11. Mice treated with anti-CTLA-4 had improved survival versus
controls (P < 0.05). Data represent combined results of two studies. CTLA-4, cytotoxic T-lymphocyte antigen-4; PD-1, programmed cell death 1;
PD-L1, programmed cell death ligand 1.
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(controls) (Figure 4).Mice treated with anti-CTLA-4 had
an increase in IFN-g but not in IL-10 or IL-6 (Figure 4).
In addition to quantitating secreted cytokines, the per-
centage of CD4 and CD8 T cells that were secreting
IFN-g was also quantitated as described previously.
Following overnight stimulation with anti-CD3 and anti-
CD28, splenocytes were treated with brefeldin for four
additional hours. Splenocytes were then fixed, permeabi-
lized and treated with an anti-IFN-g antibody. The per-
centage of cells positive for IFN-g was quantitated by
flow cytometry.The percentage of CD4 and CD8 T cells
that was positive for IFN-g was increased in mice trea-
ted with anti-PD-1 compared to control mice (P < 0.05),
(Figure 5).
A similar series of studies was performed in the two-
hit fungal sepsis model. Mice had CLP followed three
days later by Candida. Mice were treated with anti-PD-
1 or anti-PD-L1 on days 5 and 8 post CLP and spleens
harvested on Day 9. Splenocyte suspensions were pre-
pared and stimulated with anti-CD3 and anti-CD28 as
Figure 3 Single-hit and two-hit Candida infection induce increased PD-1 on T cells. Mice were injected via tail vein with 50 μl of the
0.5A600 Candida suspension and spleens harvested on days 0, 3, 5 and 7 post-infections. (A and B) Expression of PD-1 on CD4 and CD8 T cells
was determined by immunostaining and flow cytometry. There was an increase in PD-1 expression on CD4 T cells on all three time points
(P <0.05); PD-1 expression on CD8 T cells was increased at days 3 and 5 post-infection (P < 0.05). (CandD) Mice underwent CLP followed three
days later by i.v. injection of Candida. Cohorts of mice were killed and spleens harvested on days 3, 5, 9 and 12 post-CLP. PD-1 expression was
increased on CD4 and CD8 T cells at Day 3 post-CLP (prior to Candida injection) and at days 9 and 12 post-CLP (days 6 and 9 post-Candida
infection) in CD4 T cells and at Day 5 post-CLP (two days post Candida infection) in CD8 T cells (P < 0.05). CD, cluster of differentiation; CLP,
cecal ligation and puncture; PD-1, programmed cell death 1.
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described.Supernatants were harvested after 18 h and
IFN-g quantitated.Mice treated with anti-PD-1 had a
statistically significant increase in IFN-g compared to
control mice (Figure 6); there was also a trend toward
an increase in IFN-g in mice treated with anti-PD-L1.
Effects of anti-PD-L1 on intracellular IFN-g produc-
tion were quantitated in a separate series of studies.
Mice had CLP followed by Candida infection three days
later. Mice were treated with anti-PD-L1 on days 5, 8
and 11 post CLP and spleens harvested on Day 14. The
absolute number of IFN-g positive CD4 T cells was
decreased in mice that had fungal sepsis compared to
sham operated mice (Figure 7). Importantly, treatment
with anti-PD-L1 restored the percentage of IFN-g posi-
tive CD4 T cells. Anti-PD-L1 treatment also increased
the number of splenic CD8 T cells that were producing
IFN-g.
Anti-PD-1 and anti-PD-L1 increase MHC II expression on
antigen presenting cells
A decrease in macrophage and dendritic cell MHC II
expression is a hallmark of sepsis [7]. We examined the
effects of anti-PD-1 and anti-PD-L1 antibody on MHC II
mean fluorescent intensity (MFI) expression on antigen
presenting cells in the two-hit model of CLP followed by
Candida infection. Mice had CLP followed by Candida
and were treated with anti-PD-1 or anti-PD-L1 at days 5
and 8 post CLP. Spleens were harvested on Day 9 and
dendritic cells (CD11c+/MHC II hi) and macrophages (F4/
80+/MHC II intermediate) were identified by immunos-
taining as described previously [13]. The MFI, a measure
of the number of MHC II molecules expressed per cell,
was quantitated. The decrease in dendritic cell MHC II MFI
that occurred with fungal sepsis was reversed by both anti-
PD-1 and anti-PD-L1 treatment, (Figure 8). Interestingly,
Figure 4 Anti-PD-1 and anti-CTLA-4 increase splenocyte cytokine production in single-hit fungal sepsis. Mice had tail vein injection of
Candida and were treated with anti-PD-1 (days 2, 5 and 8 post-infection) or anti-CTLA-4 (days 4, 7 and 10 post-infection). Mice were killed and
spleens harvested on day 12 post-infection. Splenocytes were prepared and stimulated with anti-CD3 and anti-CD28 overnight. Supernatants
were harvested and IFN-g, IL-10 and IL-6 quantitated. Mice treated with anti-PD-1 had increases in all three cytokines compared to Candida-
infected mice that were treated with saline diluent (controls) (P <0 .05). Mice treated with anti-CTLA-4 had an increase in IFN-g only (P < 0.05).
CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte antigen-4; IFN-g, interferon gamma; IL, interleukin; PD-1, programmed cell death 1.
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anti-PD-L1 caused a greater increase in MHC II MFI com-
pared to anti-PD-1.Macrophage MHC II MFI was also
decreased in fungal sepsis and anti-PD-L1 (but not anti-PD-
1) acted to reverse this decrease.
Discussion
The present results demonstrating that blockade of PD-1,
PD-L1 or CTLA-4 leads to improved survival in both pri-
mary and secondary fungal sepsis strongly support the
concept that inhibition of T cell negative co-stimulatory
pathways represents an effective therapeutic approach to
disseminated fungal sepsis.Previous reports by three inde-
pendent groups showed that inhibition of the PD-1:PD-L1
pathway improved survival in the clinically relevant CLP
model of bacterial sepsis [23-25]. Recent studies have also
reported that inhibition of PD-1 restores T cell function
and decreases viral load in murine models of hepatitis B
and HIV-1 [29,30]. In a related fashion, our group has
reported that an antagonistic antibody to CTLA-4
improved survival in a clinically-relevant animal model of
bacterial peritonitis [28]. Additional studies havedemon-
strated that increased CTLA-4 expression adversely
affected pathogen clearance in murine models of Helico-
bacterpylori, Leishmania and Trypanosoma [31-33].
Considered together, these studies make a compelling case
that modulation of the negative co-stimulatory pathway
mediated by PD-1/PD-L1 and CTLA-4 represents a novel
and potentially highly effective approach to a broad range
of infectious agents.
The findings from the current studies showing that
blockade of negative co-stimulatory pathways improves
survival in disseminated fungal sepsisprovide additional
support for the hypothesis that immunosuppression is a
major pathophysiologic phenomenon in sepsis. Although
there are multiple interacting mechanisms responsible
for immunosuppression in sepsis, including, for example,
increased T regulatory cells, increased myeloid derived
suppressor cells, and apoptosis-induced depletion of
immune effector cells, recent studies highlight the likely
role of PD-1 mediated T cell “exhaustion” in impaired
immunity [23-25,34,35]. Guignantet al. showed that PD-
1 over-expression occurred on circulating T cells from
patients with sepsis and correlated with decreased T cell
proliferative capacity, increased secondary nosocomial
infections and mortality [26].Studies from our group
documented an increase in the percentage of PD-L1
expressing monocytes in patients who die of sepsis versus
sepsis survivors (data not shown). A recent postmortem
study from our group also demonstrated significantly
increased expression of PD-1 and PD-L1 on splenic
Figure 5 Anti-PD-1 increases IFN-g+ CD4 and CD8 T cells in fungal sepsis. Mice had tail-vein injection of Candida and were treated with
anti-CTLA-4 or anti-PD-1 as described in Figure 4. Following supernatant harvesting, splenocytes were treated with brefeldin for four hours and
then fixed, permeabilized and immunostained for CD4, CD8 and intracellular IFN-g. Flow cytometry was performed to quantitate the percentage
of CD4 and CD8 T cells that were positive for IFN-g.Anti-PD-1 but not anti-CTLA-4 increased the percentage of IFN-g+ CD4 and CD8 T cells, (P <
0.05). CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte antigen-4; IFN-g, interferon gamma; PD-1, programmed cell death 1.
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T cells and antigen presenting cells respectively in septic
versus non-septic patients [34]. This increased expression
of PD-1 and PD-L1 was associated with marked
suppression of stimulated cytokine production by spleno-
cytes from septic patients; splenocytes from septic
patients produced less than approximately 10% of the
Anti-PD-1/PD-L1 Increase IFN-J  
Figure 6 Anti-PD-L1 increases IFN-g production in two-hit fungal sepsis. Mice had CLP followed in three days by Candida injection.Anti-PD-
1 and anti-PD-L1 were administered on days 5 and 8 post CLP and spleens harvested on Day 9.Splenocyte suspensions were prepared and
stimulated overnight with anti-CD3/CD28.Supernatants were harvested at 18 h and IFN-g production quantitated.Two-hit fungal sepsis caused a
decrease in IFN-g production compared to sham (P <0.05); splenocytes from mice treated with anti-PD-1 had an increased IFN-g production
compared to septic mice not receiving antibody therapy.There was a trend toward increased IFN-g production in mice treated with anti-PD-L1
but it did not reach statistical significance. CD, cluster of differentiation; IFN-g, interferon gamma; IL, interleukin; PD-1, programmed cell death 1;
PD-L1, programmed cell death ligand 1.
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amount of cytokines produced by splenocytes from criti-
cally-ill non-septic patients. Collectively, these studies are
consistent with a major role for PD-1:PD-L1-mediated
immune suppression in patients with sepsis.
Blockade of PD-1, PD-L1 and CTLA-4 not only offers
new hope in infectious disease but also appears especially
promising in cancer therapy [21,22,36-38]. Anti-CTLA-4
antibody reinvigorated the concept of immunotherapy as a
valid approach to cancer with its success in inducing sig-
nificant remissions in patients with widely metastatic
malignant melanoma, many of whom had failed other
therapies [38]. Anti-PD-1 antibody, which has a better
safety profile compared to anti-CTLA-4, produced clinical
responses in approximately 25% of patients with a variety
of diverse tumors [36,37]. Anti-CTLA-4 and anti-PD-1
restore T cell function thereby reactivating host immunity
allowing it to eliminate tumor cells. Remarkably, many
remissions with anti-CTLA-4 and anti-PD-1 appear to be
durable, that is, they have lasted for over a year, and may
be permanent [39]. The encouraging results of cancer
immunotherapy with anti-CTLA-4 and anti-PD-1 are
highly relevant to sepsis patients because cancer and
sepsis share many of the same immunosuppressive
mechanisms,including increased T cell CTLA-4 expression
and increased PD-1 and PD-L1 expression in T cells and
monocytes, respectively, with T cell “exhaustion” [4-8,
34,35]. Sepsis, like cancer, is an ideal condition for persis-
tent antigenic exposure which is thought to be one
mechanism driving induction of PD-1/PD-L1 and T cell
dysfunction.
Although there are likely a number of mechanisms that
are responsible for the protective effect of anti-PD-1, anti-
PD-L1 and anti-CTLA-4 in sepsis, one likely mechanism
is their ability to reverse the sepsis-induced suppression in
IFN-g production. All three antibodies had demonstrable
efficacy in increasing either splenocyte IFN-g production
   ɲPD-L1 
Figure 7 Anti-PD-L1 increases IFN-g producing CD4 and CD8 T cells in fungal sepsis. Mice had CLP followed three days later by Candida
injection.The protocol for administration of anti-PD-1 and anti-PD-L1 as well as the details of splenocyte preparation and incubation were as
described in Figure 6.Following overnight stimulation with anti-CD3/CD28, cells were treated with brefeldin for four hours.Cells were then fixed,
permeabilized and stained with anti-IFN-g.Flow cytometry was performed to quantitate the number of IFN-g+ CD4 and CD8 T cells. The number
of IFN-g+ CD4 T cells was decreased in two-hit fungal sepsis compared to sham mice and sham mice treated with anti-PD-L1, (P <0.05).Septic
mice treated with anti-PD-L1 had an increase in the number of IFN-g+ CD4 and CD8 T cells compared to septic mice treated with saline diluent
(P <0.05).CD, cluster of differentiation; CLP, cecal ligation and puncture; IFN-g, interferon gamma; PD-1, programmed cell death 1; PD-L1,
programmed cell death ligand 1.
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or the percentage of IFN-g positive CD4 and/or CD8 T
cells (Figures 4, 5, 6, 7). (Note that differing effects on host
immunity have recently been observed in animals treated
with different isotypeantibodies to CTLA-4 [40].) T cells
are major producers of IFN-g, which is essential for
optimal function of monocytes and macrophages. Sepsis-
induced suppression of IFN-g production is likely a major
driving force for the immune suppression in the disorder
[41,42]. Administration of IFN-g during the immunosup-
pressive phase of sepsis has been reported to be beneficial
in several small clinical studies [41,42]. The ability of anti-
PD-1, anti-PD-L1 and anti-CTLA-4 antibodies to improve
IFN-g production may be particularly germane to fungal
sepsis. Administration of IFN-g improves outcome in
patients with chronic granulomatous disease who have
fungal sepsis. Recently, a trial of IFN-g in a small number
of patients with fungal meningitis showed that IFN-g leads
to more rapid clearing of fungal organisms from the cere-
brospinal fluid, an important clinical finding that corre-
lates with survival [14].
Another interesting finding regarding effects of the
anti-PD-1 antibody on cytokines was its action to
increase production of the pro-inflammatory cytokine IL-
6 and the immunosuppressive cytokine IL-10 (Figure 4).
The effect of anti-PD-1 to increase IL-10 in the present
study is somewhat surprising given findings by Said et al.
who reported that PD-1 induces IL-10 production in
monocytes in patients with HIV, thereby resulting in
impaired T cell activation [43]. Our findings, showing an
effect of anti-PD-1 antibody to increase IL-10 production,
Figure 8 Anti-PD-1 and anti-PD-L1 increase MHC II expression on dendritic and macrophages in fungal sepsis. Mice had CLP and three
days later were injected with Candida.Anti-PD-1 or anti-PD-L1 was administered on days 5 and 8 post-CLP. Spleens were harvested on Day 9
post-CLP and splenocytes prepared.Immunostaining for dendritic cells (CD11c+/MCH II hi) and macrophages (F4/80+/MHC II intermediate) was
performed.The mean fluorescence intensity (MFI) of dendritic cell and macrophage MHC II was decreased in fungal sepsis compared to naïve
mice (P <0.05).Both anti-PD-1 and anti-PD-L1 increased MHC II MFI in dendritic cells and macrophages in fungal sepsis (P <0.05), but anti-PD-L1
had a greater effect compared to anti-PD-1, (P <0.05). CLP, cecal ligation and puncture; IFN-g, interferon gamma; PD-1, programmed cell death 1;
PD-L1, programmed cell death ligand 1.
Chang et al. Critical Care 2013, 17:R85
http://ccforum.com/content/17/3/R85
Page 11 of 14
are similar to the report by Wong et al. who noted that
anti-PD-L-1 antibody caused an increase in both IFN-g
and IL-10 in a lymphocyte incubation study [44]. The
increase in IL-10 splenocyte production in the present
study was relatively small compared to the larger effect of
the anti-PD-1 antibody on IFN-g production (Figure 4).
Thus, we believe that the predominant effect of the anti-
PD-1 antibody is to enhance activation of T cells, a highly
beneficial effect in sepsis.
Similar to our previous findings in the CLP model of
sepsis [28], the anti-CTLA-4 antibody worsened out-
come in fungal sepsis if administered at higher doses or
too early during the course of the disease (data not
shown). No such adverse effects were observed with
anti-PD-1 or anti-PD-L1 antibody at any dose or time of
administration (data not shown). Thus, anti-PD-1 and
anti-PD-L1 appear to have a better safety profile com-
pared to anti-CTLA-4 antibody and this finding mirrors
clinical studies in cancer patients which show a lower
incidence of autoimmune effects in patients treated with
anti-PD-1 compared to anti-CTLA-4 [36-39].
Additional evidence for beneficial effects of anti-PD-1
and anti-PD-L1 on host immunity is provided by their
ability to increase MHC II expression on macrophages
and dendritic cells (Figure 8). Decreased MHC II
expression is a hallmark of sepsis and is used as a mar-
ker of immune suppression during the disorder [7].
MHC II molecules function to present microbial anti-
gens to CD4 T cells thereby activating these cells for
optimal response to the infectious challenge. Although
both anti-PD-1 and anti-PD-L1 improved dendritic cell
and macrophage MHC II expression, anti-PD-L1 had a
greater effect than anti-PD-1 (Figure 8). This more
robust effect of anti-PD-L1 antibody compared to anti-
PD-1 antibody to increase MHC II expression may be
related to the fact that PD-L1 is expressed on macro-
phages and dendritic cells and has direct suppressive
effects on these cells.
The present experimental findings providepreclinical
hypothesis-generating data which support the contention
that immuno-adjuvant therapy with anti-PD-1/PD-L1 and
anti-CTLA-4 offers a new approach to treatment of fungal
infections and likely infectious disease in general.The
remarkable efficacy of anti-PD-1 and anti-CTLA-4 anti-
body therapy to induce remissions in a relatively high per-
centage of cancer patients [36-38] is evidence that this
immunologic approach has profound effects to enhance
host immunity. Sepsis, another life threatening failure of
host immunity that shares many immune defects with
cancer, is likely amenable to this immuno-stimulatory
approach as well. Although serious autoimmune side
effects of anti-PD-1 and anti-CTLA-4 have occurred in a
small percentage of cancer patients treated with these
agents [36-38], these adverse effects would likely be less
problematic in patients with sepsis because of two factors.
First, compared to cancer patients, most septic patients
have more severe impairment in host immunity. Secondly,
most patients with sepsis would need only short-term
therapy with anti-PD-1 or anti-CTLA-4 and, therefore,
would be less likely to develop autoimmunity. Addition-
ally, anti-PD-1 antibody could be tailored to septic patients
whose peripheral circulating T cells or monocytes have
persistently increased expression of PD-1 or PD-L1,
respectively, evidence that the patients have entered an
immunosuppressive phase of the disorder. Thus, a readily
available biomarker could be used to select ideal candidate
patients for immune therapy using these agents.
Conclusions
Blockade of the negative co-stimulatory molecules PD-1,
PD-L1 and CTLA-4 improved survival in two models of
fungal sepsis. Potential mechanisms of action for the
beneficial effects of blocking negative co-stimulatory
molecules include increased IFN-g production and
increased expression of MHC II on antigen presenting
cells. If ongoing, large phase 3 studies of anti-PD-1 anti-
body in cancer patientscontinue to show its relative
safety, carefully conducted clinical trials of anti-PD-1
antibody should be conducted in patients with sepsis.
Such a novel immunologic therapy could represent a
major advance against this highly lethal disease.
Key messages
• Fungal sepsis is an increasingly important cause of
morbidity and mortality in intensive care unit
patients.
• Programmed cell death-1 (PD-1), programmed cell
death ligand-1 (PD-L1) and cytotoxic T-lymphocyte
antigen-4 (CTLA-4), are important inhibitors of
immune cell function which have be shown to be
increased in patients with sepsis.
• Antibodies to PD-1, PD-L1 and CTLA-4 improved
survival in two different models of fungal sepsis.
• Anti-PD-1 increased production of IFN-g, an
important activator of monocyte/macrophages, and
increased expression of major histocompatibility
molecule II.
• Anti-PD-1 and anti-CTLA-4 antibodies may offer a
new immunomodulatory therapeutic approach in
fungal sepsis.
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